Sutro Biopharma (NASDAQ:STRO) Stock Price Expected to Rise, Citizens Jmp Analyst Says

Sutro Biopharma (NASDAQ:STRO) had its price objective upped by stock analysts at Citizens Jmp from $23.00 to $35.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp’s price objective would indicate a potential upside of 17.63% from the company’s current price.

Several other research analysts also recently weighed in on STRO. Citigroup restated an “outperform” rating on shares of Sutro Biopharma in a research note on Friday. HC Wainwright raised shares of Sutro Biopharma from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $10.00 to $28.00 in a report on Tuesday, March 24th. Wells Fargo & Company raised Sutro Biopharma from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $8.00 to $27.00 in a research report on Tuesday, March 24th. Deutsche Bank Aktiengesellschaft lifted their price target on Sutro Biopharma from $51.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sutro Biopharma in a report on Monday, December 22nd. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $38.88.

Sutro Biopharma Price Performance

STRO opened at $29.76 on Friday. Sutro Biopharma has a 12 month low of $5.23 and a 12 month high of $30.50. The business has a 50-day moving average of $22.09 and a two-hundred day moving average of $14.61. The stock has a market capitalization of $492.95 million, a price-to-earnings ratio of -1.14 and a beta of 1.31.

Hedge Funds Weigh In On Sutro Biopharma

Large investors have recently made changes to their positions in the business. Invesco Ltd. increased its position in shares of Sutro Biopharma by 137.8% during the first quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock valued at $60,000 after purchasing an additional 53,390 shares during the period. AQR Capital Management LLC grew its holdings in shares of Sutro Biopharma by 1,052.8% during the first quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company’s stock worth $859,000 after purchasing an additional 1,206,330 shares during the last quarter. Strs Ohio bought a new position in shares of Sutro Biopharma in the first quarter worth about $99,000. Marshall Wace LLP acquired a new position in Sutro Biopharma during the 2nd quarter worth $166,000. Finally, Cerity Partners LLC boosted its holdings in Sutro Biopharma by 169.9% in the second quarter. Cerity Partners LLC now owns 105,437 shares of the company’s stock valued at $75,000 after acquiring an additional 66,372 shares during the last quarter. Institutional investors and hedge funds own 96.99% of the company’s stock.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.